vitreous detachment was created intraoperatively. No attempt was made to drain the subretinal fluid, and no laser photocoagulation was performed. No retinal breaks were identified. The vitreous cavity was filled with 20% sulfur hexafluoride gas and the patient maintained face-down positioning for 1 week.
One week postoperatively, the retinal detachment had resolved, and the visual acuity improved to 20/ 200 OD. At the 1 month visit, the visual acuity remained 20/200 OD, and the macular contour had improved ( Figure 3A) . Optical coherence tomography showed foveal cysts, but the subretinal fluid was gone ( Figure 3B ).
Shortly thereafter, the patient complained of sudden vision loss in the left eye. The visual acuity was counting fingers at 2 ft OS. The clinical appearance was very similar to the initial examination of the right eye, showing a shallow posterior pole retinal detachment with outer retinal corrugations and inner retinal cysts, with no visible retinal breaks. The patient underwent a pars plana vitrectomy, mechanical separation of the hyaloid, and gas tamponade with 20% sulfur hexafluoride gas in this eye. One week later, the visual acuity had improved to 20/200, and the subretinal fluid had resorbed, but the foveal cysts remained.
At the 3-month postoperative visit for the left eye (4 months after surgery in the right eye), the visual acuity had improved to 20/100 OD and 20/60 OS. The retina remained flat and attached in both eyes, with optical coherence tomography showing an overall decrease in the amount of detachment and a decrease in the foveal cysts in the left eye.
Comment.
Patients with XLR have a defect in the XLRS1 gene, which encodes retinoschisin, a protein that is believed to be essential to cellular adhesion. 1 The abnormal retinoschisin may cause dysfunction of the Muller cells, which results in a schisis cavity. 2 Most patients with XLR have mild to moderate vision loss due to foveal schisis, and this can gradually worsen during adulthood. 3 Cases of severe vision loss are usually due to vitreous hemorrhage or a rhegmatogenous retinal detachment. Up to 22% of patients develop a rhegmatogenous retinal detachment attributable to peripheral retinal breaks. 2 There are several reports detailing the surgical results of scleral buckling and vitrectomy for the repair of the rhegmatogenous retinal detachments in these patients. 4, 5 We are unaware of any previous reports in the literature describing nonrhegmatogenous macular retinal detachment as a cause of vision loss in XLR and could find no reference to it on a MEDLINE search.
We have described a patient with XLR who was initially seen with bilateral, sequential, macular retinal detachments, which were repaired via vitrectomy with short-acting gas tamponade. While pronounced corrugations suggest a rhegmatogenous origin, both clinical and intraoperative examinations failed to demonstrate retinal breaks, pigment, or hemorrhage in either eye. These could be exudative macular detachments. However, no other causes suggestive of an exudative process were identified, no leakage was present on the angiogram, and corrugations would not be expected. We believe that this case represents a variant of vitreomacular traction, which, when combined with the defective cellular adhesion of juvenile XLR, resulted in such a striking appearance. 6 It is possible that the traction caused an enormous schisis cavity and relief of the traction improved the retinal contour. Gas tamponade was used to aid in the closure of a possible occult inner wall hole within the schisis cavity, but this may not have been necessary. Our experience suggests that these detachments may respond well to vitrectomy surgery with removal of the posterior hyaloid in combination with shortterm gas tamponade.
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Infliximab-Associated Third Nerve Palsy
A third nerve palsy (TNP) may show gadolinium enhancement of the cisternal segment of the oculomotor nerve on magnetic resonance imaging. Causes include inflammation, infection, neoplasm, ophthalmoplegic migraine, and demyelination. Infliximab, a tumor necrosis factor (TNF) ␣ inhibitor, may cause demyelination or increase relapses in patients with multiple sclerosis. 1 We report a patient who developed a TNP associated with infliximab use. On examination, he had minimal ptosis and limitation of elevation and adduction of the right eye. Pupils were equal in size and reactivity. Visual acuity, dilated fundus examination, neurologic examination, and review of systems were unremarkable. Other medications included 400 mg of hydroxychloroquine daily and 10 mg of methotrexate weekly. He took latanoprost and carteolol hydrochloride for glaucoma.
Report of a
Results of rapid plasma reagin, fluorescent treponemal antibody (Figure 1) . After stopping infliximab administration, the diplopia and ptosis gradually resolved during 3 months. Repeat magnetic resonance imaging showed resolution of the oculomotor nerve enhancement (Figure 2) . No new neurologic symptoms had developed after 16 months' follow-up.
Comment. Infliximab is a chimeric monoclonal antibody against TNF-␣. Early studies demonstrated that anti-TNF antibodies protected animals from developing experimental autoimmune encephalomyelitis. However, a double-blind, placebocontrolled study of 168 patients with multiple sclerosis showed that patients taking an anti-TNF-␣ agent received no benefit in the treatment group. Instead, significantly more relapses occurred than in the placebo group.
1 Therefore, this class of drugs is now contraindicated in patients with multiple sclerosis. Postmarketing surveillance data in 2002 revealed 64 cases of demyelination associated with infliximab use including central nervous system demyelination, chronic inflammatory demyelinating polyradiculoneuropathy, and "neuropathy." 2 Several disorders may cause enhancement of the cisternal segment and palsy of the oculomotor nerve. The transient and isolated nature of the palsy described herein suggests demyelination. Evaluation did not reveal evidence of infection, inflammation, or migraine. Seven cases of demyelinating TNP associated with enhancement of the oculomotor nerve cisternal segment were reported in patients with multiple sclerosis. 3 Although, to our knowledge, demyelinating TNP has not been reported previously, others have described peripheral, multifocal motor neuropathy occurring 3 to 24 months after initiation of infliximab therapy. 4 The complete effect of infliximab on the immune response is not entirely understood, and therefore, its long-term safety remains unknown. Infliximab may increase the risk of demyelination, which we believe caused the TNP in our patient. Although coincidence is a possibility, physicians should be aware of the potential association when confronted with a patient receiving a TNF-␣ inhibitor who develops a demyelinating event. 
